Heidelberg Pharma AG (ETR:HPHA)

PRESS RELEASE

published on 03/09/2026 at 07:12, 2 months ago

Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Heidelberg Pharma AG announces amendment to royalty agreement with HealthCare Royalty and participation of Soleus Capital, securing financing until mid-2027. USD 20 million upfront from Soleus Capital and USD 25 million upon FDA approval of TLX250-Px

FDA Approval Heidelberg Pharma HealthCare Royalty Royalty Agreement Soleus Capital
BRIEF

published on 03/07/2026 at 02:08, 2 months 2 days ago

Heidelberg Pharma modifie son accord de redevances avec HealthCare Royalty et Soleus Capital

Heidelberg Pharma Soleus Capital Contrat De Redevances TLX250-Px Royauté Des Soins De Santé
BRIEF

published on 03/07/2026 at 02:08, 2 months 2 days ago

Heidelberg Pharma Modifies Royalty Agreement with HealthCare Royalty and Soleus Capital

Heidelberg Pharma HealthCare Royalty Royalty Agreement Soleus Capital TLX250-Px
PRESS RELEASE

published on 03/07/2026 at 02:03, 2 months 2 days ago

EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Heidelberg Pharma AG announces amendment to royalty agreement with HealthCare Royalty and partnership with Soleus Capital, securing upfront and milestone payments

FDA Approval HealthCare Royalty Heidelberg Pharma AG Royalty Agreement Soleus Capital
BRIEF

published on 01/29/2026 at 13:32, 3 months 11 days ago

Heidelberg Pharma obtient un paiement d'étape de Takeda

Développement Clinique Heidelberg Pharma Paiement D'étape Partenariat Takeda Technologie ATAC
BRIEF

published on 01/29/2026 at 13:32, 3 months 11 days ago

Heidelberg Pharma Attains Milestone Payment from Takeda

Clinical Development Heidelberg Pharma Milestone Payment ATAC Technology Takeda Partnership
PRESS RELEASE

published on 01/29/2026 at 13:27, 3 months 11 days ago

Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Heidelberg Pharma AG receives development milestone payment from partner Takeda for progress in ADC technology clinical trial

Takeda Clinical Trial Heidelberg Pharma ADC Technology Development Milestone
BRIEF

published on 12/17/2025 at 09:26, 4 months 23 days ago

Heidelberg Pharma Faces Financial Hurdles Amid Strategic Adjustments

Clinical Trials Cancer Research Cost-cutting Heidelberg Pharma Financial Challenges
BRIEF

published on 12/17/2025 at 09:26, 4 months 23 days ago

Heidelberg Pharma confrontée à des difficultés financières dans un contexte d'ajustements stratégiques

Essais Cliniques Réduction Des Coûts Heidelberg Pharma Défis Financiers Recherche Sur Le Cancer
PRESS RELEASE

published on 12/17/2025 at 09:21, 4 months 23 days ago

Heidelberg Pharma: Letter from the CEO
Heidelberg Pharma CEO addresses delays in milestone payment, emphasizing continued development of TLX250-CDx and promising phase I study results for pamlectabart tismanitin (HDP-101). Financial challenges are being addressed proactively

CEO Heidelberg Pharma Milestone Payment TLX250-CDx Pamlectabart Tismanitin

Published on 05/09/2026 at 01:55, 13 hours 40 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 13 hours 55 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 14 hours 5 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 15 hours 35 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 16 hours 34 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

Published on 05/08/2026 at 20:38, 18 hours 57 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 20 hours 22 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 20 hours 33 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 21 hours 6 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 21 hours 6 minutes ago

Designated Person Notification

View all EQS

Published on 05/07/2026 at 19:15, 1 day 20 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 20 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 20 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 20 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 20 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

News